Incidence and clinical significance of false-negative sextant prostate biopsies

Farhang Rabbani, Nicholas Stroumbakis, Bruce Kava, Michael S. Cookson, William R. Fair

Research output: Contribution to journalArticle

251 Citations (Scopus)

Abstract

Purpose: Since most patients do not undergo repeat sextant prostate biopsies after a biopsy is positive for prostate cancer, the true incidence of false-negative biopsies is not well defined. We assess the incidence and clinical significance of false-negative sextant prostate biopsies in patients undergoing radical prostatectomy. Materials and Methods: A total of 118 patients with biopsy proved prostate cancer underwent repeat sextant prostate biopsy before enrollment in a prospective randomized trial of radical prostatectomy with or without neoadjuvant hormonal therapy. Clinical parameters were assessed to determine potential sources of bias. Pathological parameters and prostate specific antigen relapse-free survival rates were compared to determine the clinical significance of false-negative biopsies. ResultS: Of the 118 patients 27 (23%) had a negative repeat sextant biopsy. Except for initial clinical stage, no differences were noted in the clinical or pathological parameters, or prostate specific antigen relapse rates in patients with negative versus positive repeat biopsies. Conclusions: Our findings suggest that this 23% incidence of false-negative biopsies represents significant cancer. This relatively high incidence is important to consider in treatment modalities in which prostate biopsy may be performed to determine response to therapy.

Original languageEnglish
Pages (from-to)1247-1250
Number of pages4
JournalJournal of Urology
Volume159
Issue number4
DOIs
StatePublished - Apr 1 1998
Externally publishedYes

Fingerprint

Prostate
Biopsy
Incidence
Prostate-Specific Antigen
Prostatectomy
Prostatic Neoplasms
Recurrence
Neoadjuvant Therapy
Survival Rate
Therapeutics

Keywords

  • Biopsy
  • Needle
  • Prostate
  • Prostatic neoplasms
  • Ultrasonography

ASJC Scopus subject areas

  • Urology

Cite this

Incidence and clinical significance of false-negative sextant prostate biopsies. / Rabbani, Farhang; Stroumbakis, Nicholas; Kava, Bruce; Cookson, Michael S.; Fair, William R.

In: Journal of Urology, Vol. 159, No. 4, 01.04.1998, p. 1247-1250.

Research output: Contribution to journalArticle

Rabbani, Farhang ; Stroumbakis, Nicholas ; Kava, Bruce ; Cookson, Michael S. ; Fair, William R. / Incidence and clinical significance of false-negative sextant prostate biopsies. In: Journal of Urology. 1998 ; Vol. 159, No. 4. pp. 1247-1250.
@article{0507aceed97043be9146d34e9df1be9f,
title = "Incidence and clinical significance of false-negative sextant prostate biopsies",
abstract = "Purpose: Since most patients do not undergo repeat sextant prostate biopsies after a biopsy is positive for prostate cancer, the true incidence of false-negative biopsies is not well defined. We assess the incidence and clinical significance of false-negative sextant prostate biopsies in patients undergoing radical prostatectomy. Materials and Methods: A total of 118 patients with biopsy proved prostate cancer underwent repeat sextant prostate biopsy before enrollment in a prospective randomized trial of radical prostatectomy with or without neoadjuvant hormonal therapy. Clinical parameters were assessed to determine potential sources of bias. Pathological parameters and prostate specific antigen relapse-free survival rates were compared to determine the clinical significance of false-negative biopsies. ResultS: Of the 118 patients 27 (23{\%}) had a negative repeat sextant biopsy. Except for initial clinical stage, no differences were noted in the clinical or pathological parameters, or prostate specific antigen relapse rates in patients with negative versus positive repeat biopsies. Conclusions: Our findings suggest that this 23{\%} incidence of false-negative biopsies represents significant cancer. This relatively high incidence is important to consider in treatment modalities in which prostate biopsy may be performed to determine response to therapy.",
keywords = "Biopsy, Needle, Prostate, Prostatic neoplasms, Ultrasonography",
author = "Farhang Rabbani and Nicholas Stroumbakis and Bruce Kava and Cookson, {Michael S.} and Fair, {William R.}",
year = "1998",
month = "4",
day = "1",
doi = "10.1016/S0022-5347(01)63574-2",
language = "English",
volume = "159",
pages = "1247--1250",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Incidence and clinical significance of false-negative sextant prostate biopsies

AU - Rabbani, Farhang

AU - Stroumbakis, Nicholas

AU - Kava, Bruce

AU - Cookson, Michael S.

AU - Fair, William R.

PY - 1998/4/1

Y1 - 1998/4/1

N2 - Purpose: Since most patients do not undergo repeat sextant prostate biopsies after a biopsy is positive for prostate cancer, the true incidence of false-negative biopsies is not well defined. We assess the incidence and clinical significance of false-negative sextant prostate biopsies in patients undergoing radical prostatectomy. Materials and Methods: A total of 118 patients with biopsy proved prostate cancer underwent repeat sextant prostate biopsy before enrollment in a prospective randomized trial of radical prostatectomy with or without neoadjuvant hormonal therapy. Clinical parameters were assessed to determine potential sources of bias. Pathological parameters and prostate specific antigen relapse-free survival rates were compared to determine the clinical significance of false-negative biopsies. ResultS: Of the 118 patients 27 (23%) had a negative repeat sextant biopsy. Except for initial clinical stage, no differences were noted in the clinical or pathological parameters, or prostate specific antigen relapse rates in patients with negative versus positive repeat biopsies. Conclusions: Our findings suggest that this 23% incidence of false-negative biopsies represents significant cancer. This relatively high incidence is important to consider in treatment modalities in which prostate biopsy may be performed to determine response to therapy.

AB - Purpose: Since most patients do not undergo repeat sextant prostate biopsies after a biopsy is positive for prostate cancer, the true incidence of false-negative biopsies is not well defined. We assess the incidence and clinical significance of false-negative sextant prostate biopsies in patients undergoing radical prostatectomy. Materials and Methods: A total of 118 patients with biopsy proved prostate cancer underwent repeat sextant prostate biopsy before enrollment in a prospective randomized trial of radical prostatectomy with or without neoadjuvant hormonal therapy. Clinical parameters were assessed to determine potential sources of bias. Pathological parameters and prostate specific antigen relapse-free survival rates were compared to determine the clinical significance of false-negative biopsies. ResultS: Of the 118 patients 27 (23%) had a negative repeat sextant biopsy. Except for initial clinical stage, no differences were noted in the clinical or pathological parameters, or prostate specific antigen relapse rates in patients with negative versus positive repeat biopsies. Conclusions: Our findings suggest that this 23% incidence of false-negative biopsies represents significant cancer. This relatively high incidence is important to consider in treatment modalities in which prostate biopsy may be performed to determine response to therapy.

KW - Biopsy

KW - Needle

KW - Prostate

KW - Prostatic neoplasms

KW - Ultrasonography

UR - http://www.scopus.com/inward/record.url?scp=0031897085&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031897085&partnerID=8YFLogxK

U2 - 10.1016/S0022-5347(01)63574-2

DO - 10.1016/S0022-5347(01)63574-2

M3 - Article

C2 - 9507846

AN - SCOPUS:0031897085

VL - 159

SP - 1247

EP - 1250

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 4

ER -